来源:Gangtise投研九源基因(02566.HK)2024年度业绩发布会:九源基因成立于1993年,专注生物医药领域,拥有9款商业化产品,涵盖肿瘤、骨科、血液和代谢四大领域。2024年肿瘤产品占营收19.47%,血液产品占9.96%。其骨科重点产品为国内首款含RHBNP蛋白的骨复合材料,适用于多种骨修复场景。公司正布局院内和院外市场,尤其注重线上互联网药店合作,已与近岸蛋白签署合作协议,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.